Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| CODX | Co-Diagnostics | $3.56 | -$2.42 | -40.47% | 174.6K | $13M | $3.56$46.50 |
| TVTX | Travere Therapeutics | $22.71 | -$11.39 | -33.39% | 9.8M | $3.1B | $12.91$42.13 |
| ATRA | Atara Biotherapeutics | $4.57 | -$1.32 | -22.36% | 1.7M | $42M | $4.45$19.15 |
| ELAB | Pmgc | $4.25 | -$1.02 | -19.36% | 379.8K | $2.7M | $3.54$398.86 |
| RGC | Regencell Bioscience | $36.24 | -$7.87 | -17.84% | 551.5K | $22B | $0.09$83.60 |
| FIGG | Themes ETF Trust - Leverage Shares 2x Long Fig Daily ETF | $3.61 | -$0.71 | -16.35% | 782.3K | - | $3.60$16.34 |
| EMAT | Evolution Metals & Technologies | $13.95 | -$2.50 | -15.20% | 44.8K | $47M | $7.05$24.37 |
| LGND | Ligand Pharmaceuticals | $180.44 | -$26.37 | -12.75% | 411.6K | $4.1B | $93.58$212.49 |
| AHT | Ashford Hospitality Trust | $3.79 | -$0.53 | -12.27% | 188.2K | $28M | $2.90$10.35 |
| PDDL | GraniteShares ETF Trust - GraniteShares 2x Long Pdd Daily ETF | $27.00 | -$3.71 | -12.09% | 45.9K | - | $24.19$43.73 |
Related Articles
Featured Article
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
2 Real Estate Stocks to Avoid Like the Plague
Liz Brumer|Feb 18, 2022
These two stocks are headed in the wrong direction, and the risks far outweigh any potential reward.
Advertisement
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
Keith Speights|May 4, 2021
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
3 Signs the Ligand Short Squeeze Is Over
Jason Hawthorne|Apr 22, 2021
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
Co-Diagnostics: Buy the Dip?
Cory Renauer|Mar 29, 2021
Analysts following this coronavirus stock have darkened their post-pandemic outlook.
What Investors Didn't Like About Co-Diagnostics' Q4 Update
Keith Speights|Mar 26, 2021
The company missed earnings expectations and hinted at slowing growth in 2021.
Co-Diagnostics Names New CFO and CSO
Eric Volkman|Feb 23, 2021
With the latter appointment, the company's founder moves into a more advisory role.
Forget Gamestop! This Highly Shorted Stock Is a Strong Buy Now
Jason Hawthorne|Feb 9, 2021
The unusual biotech could be a bitter pill for short sellers to swallow.
Short-Sellers Have These 3 ETFs in Their Sights
Dan Caplinger|Feb 3, 2021
Should investors watch for a squeeze?
